Transcription efficiency of tamoxifen citrate-loaded β-cyclodextrin nanoparticles

Marsaud, 2003, Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor (ER), differentially affect ER extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells, Mol Endocrinol., 17, 2013, 10.1210/me.2002-0269 Shiau, 1998, The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen, Cell, 95, 927, 10.1016/S0092-8674(00)81717-1 Jordan, 2001, Molecular Classification of Estrogens, Cancer Research, 61, 6619 Hanstein, 2004, Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer, European Journal of Endocrinology, 150, 243, 10.1530/eje.0.1500243 Clarke, 2001, SKAAR T.C.- Cellular and molecular pharmacology of antiestrogen action and resistance, Pharmacological Reviews, 53, 25 Peters-Engl, 1999, Association between endometrial cancer and tamoxifen treatment of breast cancer, Breast Cancer Treat., 54, 255, 10.1023/A:1006126411210 Cohen, 2004, Endometrial pathologies associated with postmenopausal tamoxifen treatment.-, Gynecol. Oncol., 94, 256, 10.1016/j.ygyno.2004.03.048 Delima, 2003, Effects of low dose tamoxifen on normal breast tissue from premenopausal women, Eur. J. Cancer, 39, 891, 10.1016/S0959-8049(02)00530-0 Chawla, 2002, Biodegradable poly(ε-caprolactone) nanoparticles for tumor targeted delivery of tamoxifen.-, Int. J. Pharm., 249, 127, 10.1016/S0378-5173(02)00483-0 Brigger, 2001, P. COUVREUR P., Tamoxifen encapsulation within polyethylene glycol-coated nanospheres.-, Int. J. Pharm., 214, 37, 10.1016/S0378-5173(00)00628-1 Duchene, 1999, Cyclodextrins in targeting. applications to nanoparticles, Adv. Drug Del. Rev., 36, 29, 10.1016/S0169-409X(98)00053-2 Memisoglu, 2002, Amphiphilic β-cyclodextrins modified on the primary face: synthesis, characterization and evaluation of their potential as novel excipients in the preparation of nanocapsules, J. Pharm. Sci., 91, 1214, 10.1002/jps.10105 Skiba, 1992, Preparation et utilisation des nouveaux systemes colloidaux dispersibles a base de cyclodextrines, sous forme de nanospheres, French Patent, 92, 07287 Geze, 2002, Influence of chemical structure of zamphiphilic β-cyclodextrins on their ability to form stable nanoparticles, Int. J. Pharm., 242, 301, 10.1016/S0378-5173(02)00192-8 Hincal, 2003, β-cyclodextrines amphiphiles: evaluation de nouveaux excipients pour la preparation de nanoparticules pour l'administration par voie parenterale ou topique. Bull. Tech, Gattefossé, 96, 35 Dubes, 2003, Scanning electron microscopy and atomic force microscopy imaging of solid lipid nanoparticles derived from amphiphilic cyclodextrins, Eur. J. Pharm. Biopharm., 55, 279, 10.1016/S0939-6411(03)00020-1 Fessi, 1988 MEMISOGLU-BILENSOY E., VURAL I., RENOIR J.M., BOCHOT A., DUCHENE D., HINCAL A.A. Tamoxifen citrate loaded β- CDC6 nanoparticles: in vitro characterization and cytotoxicity. J. Cont. Rel., submitted. Gagne, 1994, Stable luciferase transfected cells for studying steroid receptor biological activity, J. Biolumin Chemilumin., 9, 201, 10.1002/bio.1170090314 Ameller, 2003, In vitro and in vivo biologic evaluation of long-circulating biodegradable drug carriers loaded with the pure antiestrogen RU 58668, Int. J. Cancer, 106, 446, 10.1002/ijc.11248 Ameller, 2004, Drug delivery systems for œstrogenic hormones and antagonists: the need for selective targeting in estradiol-dependent cancers, J. Ster. Biochem. Mol. Biol., 92, 1, 10.1016/j.jsbmb.2004.05.006 MAILLARD S., AMELLER T., GAUDUCHON J., GOUILLEUX F., LEGRAND P., MARSAUD V., FATTAL E., SOLA B., RENOIR J-M. Innovative drug delivery nanosystems improve the anti-tumor activity in vitro and in vivo of anti-estrogens in human breast cancer and multiple myeloma. J. Ster. Biochem. Mol. Biol., in press.